Physician profile
Patrick J Oleary
NPI 1942278890
$4,012.64
in general payments reported to CMS, 2019-2025
21 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2021: $201 · 2022: $647 · 2023: $1,255 · 2024: $1,016 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,560 · Travel and Lodging: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.38 |
| Travel and Lodging | $364.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $922.13 | 2021-2025 | |
| Medtronic, INC. | $589.87 | 2022-2024 | Mazor X System |
| Janssen Pharmaceuticals, INC | $354.39 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $319.08 | 2023-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $253.68 | 2019-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.48 | 2022-2025 | Jardiance |
| Amgen INC. | $205.74 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $185.92 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.37 | 2023-2025 | Lifevest |
| Cvrx, INC. | $143.06 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $141.93 | 2021-2025 | |
| Scpharmaceuticals INC. | $130.67 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $76.62 | 2023-2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $72.54 | 2025 | Sapien 3 Ultra Resilia |
| Biotronik INC. | $63.82 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.92 | 2023-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $37.91 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $33.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $26.61 | 2022-2024 | Farxiga |
| Esperion Therapeutics, INC. | $19.80 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $17.82 | 2025 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Oleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.